Article

The use of catalytically dead Cas9 to identfy key transcription regulators in triple negative breast cancer

2019-01-01

Abstract excerpt

Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancer cases. It tends to be aggressive, high-grade and poorly differentiated tumour with poor clinical outcome. Lack of expression of oestrogen, progesterone receptors, and human epidermal growth factor receptor 2 make TNBC patients ineligible to hormonal therapy. For these reasons the identification of novel clinical targets sti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5473482f-45d7-5144-ba41-990b3b1db40a
DOI: 10.17863/cam.55234

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The use of catalytically dead Cas9 to identfy key transcription regulators in triple negative breast cancerDOI 10.17863/cam.55234Read

Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer ResearchSemantic proximity Read

CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and TherapySemantic proximity Read

Advances in breast cancer research using CRISPR/Cas9 systemSemantic proximity Read

Identifying Novel Therapeutic Targets for Overcoming TNBC Chemo Resistance Through Comprehensive CRISPR-Cas9 Genome ScreeningSemantic proximity Read

CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scopeSemantic proximity Read

Proteomic Analysis of CRISPR Cas 9 Mediated Mdig Deletion in Triple Negative Breast Cancer CellsSemantic proximity Read

Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeuticsSemantic proximity Read

CRISPR-based therapeutic targeting of signaling pathways in breast cancerSemantic proximity Read

Exploring ID4 as a Driver of Aggression and a Therapeutic Target in Triple-Negative Breast CancerSemantic proximity Read

NEDD8 loss causes cancer vulnerability to immune checkpoint blockade in triple-negative breast cancerSemantic proximity Read

Transcriptomic and cellular analyses of CRISPR/Cas9-mediated edition of FASN show inhibition of aggressive characteristics in breast cancer cells.Semantic proximity Read

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancerSemantic proximity Read